HC Wainwright Has Optimistic Outlook of CorMedix Q4 Earnings

CorMedix Inc (NASDAQ:CRMD) – Equities research analysts at HC Wainwright increased their Q4 2025 earnings estimates for CorMedix in a report released on Thursday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.94 for the quarter, up from their previous forecast of $0.90. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2029 earnings at $2.57 EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a report on Wednesday, October 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price target on shares of CorMedix in a report on Tuesday, September 9th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of CorMedix in a research report on Wednesday. D Boral Capital raised CorMedix from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, Zacks Research upgraded CorMedix from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 4th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, CorMedix has an average rating of “Buy” and a consensus price target of $18.33.

CorMedix Stock Performance

CRMD stock traded up $0.09 during trading on Friday, reaching $11.30. 484,251 shares of the company traded hands, compared to its average volume of 2,314,260. The company has a market capitalization of $885.48 million, a price-to-earnings ratio of 15.05 and a beta of 1.80. The business has a 50 day simple moving average of $11.41 and a 200 day simple moving average of $12.05. CorMedix has a 12 month low of $5.60 and a 12 month high of $17.43.

CorMedix (NASDAQ:CRMD) last posted its earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.78. The company had revenue of $2.73 million during the quarter, compared to analyst estimates of $65.63 million. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.CorMedix’s revenue was up 810.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.05) earnings per share. CorMedix has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Hedge Funds Weigh In On CorMedix

Institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas purchased a new position in CorMedix during the first quarter valued at approximately $98,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of CorMedix during the 2nd quarter worth about $270,000. Hussman Strategic Advisors Inc. acquired a new position in CorMedix in the 2nd quarter worth about $776,000. Swiss National Bank purchased a new stake in shares of CorMedix in the first quarter valued at approximately $724,000. Finally, Trexquant Investment LP lifted its holdings in CorMedix by 588.9% during the first quarter. Trexquant Investment LP now owns 135,487 shares of the company’s stock valued at $835,000 after purchasing an additional 115,819 shares in the last quarter. Hedge funds and other institutional investors own 34.18% of the company’s stock.

Insider Activity at CorMedix

In other CorMedix news, CEO Joseph Todisco sold 50,000 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $13.00, for a total transaction of $650,000.00. Following the sale, the chief executive officer owned 509,496 shares in the company, valued at approximately $6,623,448. The trade was a 8.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Elizabeth Hurlburt sold 41,121 shares of the firm’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $13.08, for a total value of $537,862.68. Following the completion of the transaction, the chief operating officer owned 176,990 shares of the company’s stock, valued at approximately $2,315,029.20. The trade was a 18.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 163,997 shares of company stock worth $2,163,617 in the last quarter. 3.10% of the stock is owned by insiders.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.